Crizotinib joins first-line treatment of NSCLC

Crizotinib joins first-line treatment

In recent years, it has become a new favorite in targeted therapy research. Among patients, the positive rate of rearrangement is about % to %. The probability of fusion is high in patients with adenocarcinoma who have never smoked or smoked lightly. Compared with negative patients, positive patients are younger but have a worse prognosis. .

Crizotinib is a dual blocker of the gene or its variants. Two multicenter single-arm clinical trials showed that crizotinib has significant therapeutic activity in patients with positive tumors.

One is the expansion cohort study of part 1 of the R study. A total of 20 patients were included. The objective response rate (RR) of the crizotinib group was %, and the median duration of response was weeks.

Another study is R, in which 10 patients with positive advanced disease who failed previous chemotherapy (% of patients had received at least 3 chemotherapy regimens) from 3 countries were treated with crizotinib. The results showed that the patient's RR was %, and the median duration of response was weeks.

The most common adverse reactions (%) observed in both studies were visual impairment, nausea, diarrhea, edema, and constipation. Based on the results of the above two studies, crizotinib was approved in the United States for first-line treatment of locally advanced or metastatic disease.

Can crizotinib be used as second-line treatment? There is currently an ongoing randomized phase III clinical study (R) comparing crizotinib with other second-line treatment options, and we are looking forward to the publication of the results.

The addition of crizotinib to first-line treatment is undoubtedly a major breakthrough in targeted therapy for patients. However, despite the relatively high response rate (%), patients who are effective in crizotinib treatment are usually in the first year of treatment. Resistance will occur after treatment, so further research and exploration remains to determine the mechanism of resistance to crizotinib and how to overcome resistance.

Address: Zhongguancun Building, Beisihuan Middle Road, Haidian District, Beijing
Company name: Beijing Mingkang Trading Co., Ltd.
Telephone:
Number:
Contact Person: Miss Chen